DexCom, Inc. (NASDAQ:DXCM) Files An 8-K Other EventsItem 8.01
On June 12, 2017, to that certain Purchase Agreement (the “Purchase Agreement”), dated as of May 8, 2017, by and among the initial purchasers and DexCom, Inc. (“DexCom”), the initial purchasers purchased an additional $50 million aggregate principal amount of 0.75% Convertible Senior Notes due 2022 to cover over-allotments in a private placement to qualified institutional buyers to Rule 144A under the Securities Act of 1933, as amended.
About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and a mobile application on the patient’s iPhone to transmit glucose information.
